Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + adrenaline is a combination of the local anesthetic lidocaine (2%) and the vasoconstrictor adrenaline (epinephrine, 1:100,000) used as a topical intervention. Developed for clinical study by Dow University of Health Sciences, it is applied via soaked gauze to skin graft donor sites, particularly on the thigh, in patients with non-healing wounds or burns requiring split-thickness skin grafting. Lidocaine provides analgesia by blocking voltage-gated sodium channels, while adrenaline induces local vasoconstriction through adrenergic receptor agonism. This dual action aims to minimize perioperative bleeding, reduce the frequency of dressing changes, and alleviate postoperative pain within the first 24 hours of skin graft harvesting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + adrenaline.